Technologies and Resources for Core Laboratories

西弗吉尼亚临床医学中心核心实验室的技术和资源 翻译科学研究所(WVCTSI)支持对快速翻译至关重要的研究基础设施 创新对西弗吉尼亚州人的健康产生积极影响。重要的是，技术核心利用 之前在西弗吉尼亚州的重大创意投资，同时带来令人兴奋的创新来支持临床和 翻译(C/T)调查人员的努力。本核心中描述的资源是提供 基础设施，以吸引和培训C/T科学家，重点是基本的管道开发以及 未来一代C/T调查员的多样性。技术核心将在全州范围内利用强大的 通过与西弗吉尼亚大学(WVU)、马歇尔大学(MU)、NIOSH和 在上一个供资期间得到加强的世界卫生组织卫生和卫生人力资源。新的技术能力将是 提供给调查人员及其受训人员，以支持审问当前的、尖锐的问题以及 做好应对新出现的和未来的公共卫生危机的准备。在范围和重点上灵活的能力 能够在技术上和智力上得到支持的研究是核心的核心。具体目标 这将使我们在实现这些目标方面取得的进展包括：(1)开发和优化分子和 基于蛋白质的诊断分析，并通过自动化管道支持新的领先化合物优化 建立分子医学实验室(MML)，(2)能够调查吸入对健康的影响 通过最先进的吸入毒理学设施(ITox)和(3)支持与农村社区相关的暴露 新发传染病病原体的翻译调查。关注整个技术 核心是通过将所有活动与WVCTSI优先卫生领域联系起来提供的，以避免投资和 能源，并最大限度地进行投资，以实现重大和可衡量的成果。相关性通过以下方式获得 在与临床应用相关的每个目标的设计和重点方面绝对勤奋。总而言之，这是 结果影响我们对感兴趣的特定疾病的理解，并可能对 西弗吉尼亚人的健康，同时为更广泛的科学界做出贡献。

The Technology and Resources for Core Laboratories Core (Technology Core) of the West Virginia Clinical and Translational Science Institute (WVCTSI) supports research infrastructure critical for rapid translation of innovation to positively impact the health of West Virginians. Importantly, the Technology Core leverages the significant previous IDeA investment in West Virginia, while bringing exciting innovation to support clinical and translational (C/T) investigators’ efforts. Resources described in this Core are essential in providing infrastructure to engage and train C/T scientists with a focus on essential pipeline development as well as diversity of the future generation of C/T investigators. The Technology Core will leverage a strong statewide infrastructure through partnerships with West Virginia University (WVU), Marshall University (MU), NIOSH and the WV DHHR that has been strengthened during the previous funding period. New technical capacity will be provided to investigators and their trainees to support interrogation of current, acute, problems as well as being positioned to take on emerging and future public health crises. The capacity to be nimble in the scope and focus of research that can be supported, both technically and intellectually, is central to the Core. The specific aims that will operationalize our progress towards these goals include to: (1) develop and optimize molecular and protein-based diagnostic assays and support lead compound optimization via an automated pipeline in the newly established Molecular Medicine Laboratory (MML), (2) enable investigations of the health effects of inhalation exposures relevant to rural communities via the state of the art inhalation toxicology facility (iTox) and (3) support translational investigations of pathogens underlying emerging infectious diseases. Focus across the Technology Core is provided by tethering all activities to WVCTSI priority health areas to avoid diffusion of investment and energy, and maximize investment to achieve significant and measurable outcomes. Relevance is obtained by absolute diligence in the design and focus of each aim connecting to a clinical application. In combination, this results in impact on our understanding of specific diseases of interest, and the potential to impact positively on the health of West Virginians while contributing to the broader scientific community.